



ASX Announcement | 22 October 2019
Althea Group Holdings (ASX:AGH)

Company Announcements Office
Australian Securities Exchange
Level 4, North Tower, Rialto
525 Collins Street
MELBOURNE VIC 3000

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Act")

ALTHEA GROUP HOLDINGS LIMITED (ASX Code: AGH) ("**Company**") has today issued 210,000 fully paid ordinary shares (comprised of 180,000 shares to an entity controlled by Andrew Newbold and 30,000 shares to Taylor Dobson Perpetual Pty Ltd, an entity controlled by Penny Dobson and her husband) ("**Placement Shares**") pursuant to the institutional placement announced by the Company on 25 July 2019 and subsequent shareholder approval received on 14 October 2019.

The Company advises that:

- the Placement Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- this notice is being given under section 708A(5)(e) of the Act;
- as at the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the Act as they apply to it; and
 - section 674 of the Act; and
- as at the date of this notice, there is no excluded information of the type referred to in subsections 708A(7) and 708A(8) of the Act that is required to be set out in this notice.

Robert Meissner
Company Secretary

For further enquiries, please contact:

Althea

Joshua Fegan
Managing Director and CEO
Pulse Health Limited
T: 1300 70 20 20
E: contact@althea.com.au

Media Enquiries

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com

Australian Investors

PAC Partners Securities
T: +61 8633 9834
E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life